Annual EBIT
-$88.41 M
-$3.51 M-4.13%
December 31, 2023
Summary
- As of February 7, 2025, ALT annual earnings before interest & taxes is -$88.41 million, with the most recent change of -$3.51 million (-4.13%) on December 31, 2023.
- During the last 3 years, ALT annual EBIT has fallen by -$33.96 million (-62.37%).
- ALT annual EBIT is now -27278.60% below its all-time high of $325.30 thousand, reached on December 31, 2005.
Performance
ALT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$22.84 M
+$1.80 M+7.31%
September 30, 2024
Summary
- As of February 7, 2025, ALT quarterly earnings before interest & taxes is -$22.84 million, with the most recent change of +$1.80 million (+7.31%) on September 30, 2024.
- Over the past year, ALT quarterly EBIT has increased by +$8.80 million (+27.81%).
- ALT quarterly EBIT is now -1115.92% below its all-time high of $2.25 million, reached on June 30, 2007.
Performance
ALT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$103.51 M
-$2.20 M-2.17%
September 30, 2024
Summary
- As of February 7, 2025, ALT TTM earnings before interest & taxes is -$103.51 million, with the most recent change of -$2.20 million (-2.17%) on September 30, 2024.
- Over the past year, ALT TTM EBIT has dropped by -$15.10 million (-17.08%).
- ALT TTM EBIT is now -11561.63% below its all-time high of $903.10 thousand, reached on June 30, 2006.
Performance
ALT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ALT EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.1% | +27.8% | -17.1% |
| 3 y3 years | -62.4% | +31.8% | -23.4% |
| 5 y5 years | -96.4% | -107.7% | -403.1% |
ALT EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -4.1% | +8.9% | -42.2% | +27.8% | -31.7% | at low |
| 5 y | 5-year | -329.7% | +8.9% | -457.5% | +31.8% | -403.1% | at low |
| alltime | all time | <-9999.0% | +8.9% | -1115.9% | +31.8% | <-9999.0% | at low |
Altimmune EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$22.84 M(-7.3%) | -$103.51 M(+2.2%) |
| Jun 2024 | - | -$24.64 M(+1.0%) | -$101.31 M(+9.3%) |
| Mar 2024 | - | -$24.39 M(-22.9%) | -$92.73 M(+4.9%) |
| Dec 2023 | -$88.41 M(+4.1%) | -$31.64 M(+53.3%) | -$88.41 M(+12.5%) |
| Sep 2023 | - | -$20.64 M(+28.5%) | -$78.62 M(-3.7%) |
| Jun 2023 | - | -$16.06 M(-20.0%) | -$81.62 M(-4.7%) |
| Mar 2023 | - | -$20.07 M(-8.1%) | -$85.61 M(+0.8%) |
| Dec 2022 | -$84.90 M(-12.5%) | -$21.84 M(-7.6%) | -$84.90 M(-2.4%) |
| Sep 2022 | - | -$23.65 M(+18.0%) | -$87.01 M(-10.1%) |
| Jun 2022 | - | -$20.04 M(+3.5%) | -$96.84 M(-4.7%) |
| Mar 2022 | - | -$19.37 M(-19.1%) | -$101.60 M(+4.7%) |
| Dec 2021 | -$97.08 M(+78.3%) | -$23.95 M(-28.5%) | -$97.08 M(+15.8%) |
| Sep 2021 | - | -$33.48 M(+35.0%) | -$83.86 M(+22.2%) |
| Jun 2021 | - | -$24.80 M(+67.0%) | -$68.64 M(+10.4%) |
| Mar 2021 | - | -$14.85 M(+38.4%) | -$62.17 M(+14.2%) |
| Dec 2020 | -$54.45 M(+164.6%) | -$10.73 M(-41.2%) | -$54.45 M(+13.9%) |
| Sep 2020 | - | -$18.25 M(-0.5%) | -$47.82 M(+17.9%) |
| Jun 2020 | - | -$18.34 M(+157.3%) | -$40.57 M(+58.4%) |
| Mar 2020 | - | -$7.13 M(+74.0%) | -$25.61 M(+24.5%) |
| Dec 2019 | -$20.58 M(-54.3%) | -$4.10 M(-62.7%) | -$20.58 M(-52.9%) |
| Sep 2019 | - | -$11.00 M(+224.8%) | -$43.69 M(+22.4%) |
| Jun 2019 | - | -$3.39 M(+61.5%) | -$35.71 M(-16.9%) |
| Mar 2019 | - | -$2.10 M(-92.3%) | -$42.96 M(-4.6%) |
| Dec 2018 | -$45.02 M(-13.3%) | -$27.21 M(+803.0%) | -$45.02 M(+51.3%) |
| Sep 2018 | - | -$3.01 M(-71.7%) | -$29.75 M(-48.9%) |
| Jun 2018 | - | -$10.63 M(+155.4%) | -$58.17 M(+12.9%) |
| Mar 2018 | - | -$4.16 M(-65.1%) | -$51.55 M(-0.7%) |
| Dec 2017 | -$51.90 M(+369.8%) | -$11.94 M(-62.0%) | -$51.90 M(+20.7%) |
| Sep 2017 | - | -$31.44 M(+684.5%) | -$43.01 M(+162.9%) |
| Jun 2017 | - | -$4.01 M(-11.3%) | -$16.36 M(+17.2%) |
| Mar 2017 | - | -$4.52 M(+48.0%) | -$13.96 M(+30.5%) |
| Dec 2016 | -$11.05 M(+1189.8%) | -$3.05 M(-36.2%) | -$10.70 M(+25.0%) |
| Sep 2016 | - | -$4.79 M(+197.7%) | -$8.56 M(+70.8%) |
| Jun 2016 | - | -$1.61 M(+28.1%) | -$5.01 M(-12.4%) |
| Mar 2016 | - | -$1.25 M(+37.3%) | -$5.72 M(+93.4%) |
| Dec 2015 | -$856.60 K | -$913.60 K(-26.1%) | -$2.96 M(-42.4%) |
| Sep 2015 | - | -$1.24 M(-46.6%) | -$5.13 M(-39.3%) |
| Jun 2015 | - | -$2.32 M(-253.6%) | -$8.45 M(+29.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $1.51 M(-148.9%) | -$6.52 M(-36.0%) |
| Dec 2014 | -$10.19 M(-9.7%) | -$3.09 M(-32.3%) | -$10.19 M(-10.9%) |
| Sep 2014 | - | -$4.56 M(+1070.7%) | -$11.44 M(+6.8%) |
| Jun 2014 | - | -$389.20 K(-82.0%) | -$10.71 M(-6.4%) |
| Mar 2014 | - | -$2.16 M(-50.2%) | -$11.45 M(+10.3%) |
| Dec 2013 | -$11.29 M(+156.6%) | -$4.34 M(+13.3%) | -$10.38 M(+44.0%) |
| Sep 2013 | - | -$3.83 M(+240.2%) | -$7.21 M(+108.3%) |
| Jun 2013 | - | -$1.13 M(+3.2%) | -$3.46 M(+16.7%) |
| Mar 2013 | - | -$1.09 M(-6.4%) | -$2.96 M(-32.6%) |
| Dec 2012 | -$4.40 M(+17.5%) | -$1.17 M(+1369.1%) | -$4.40 M(+78.0%) |
| Sep 2012 | - | -$79.30 K(-87.4%) | -$2.47 M(+2.3%) |
| Jun 2012 | - | -$629.10 K(-75.1%) | -$2.42 M(-42.6%) |
| Mar 2012 | - | -$2.53 M(-431.0%) | -$4.21 M(+12.5%) |
| Dec 2011 | -$3.74 M(-87.1%) | $763.20 K(-3333.9%) | -$3.74 M(-78.1%) |
| Sep 2011 | - | -$23.60 K(-99.0%) | -$17.11 M(-16.3%) |
| Jun 2011 | - | -$2.42 M(+17.6%) | -$20.45 M(-13.2%) |
| Mar 2011 | - | -$2.06 M(-83.7%) | -$23.57 M(-18.5%) |
| Dec 2010 | -$28.91 M(+11.3%) | -$12.60 M(+274.6%) | -$28.91 M(+29.4%) |
| Sep 2010 | - | -$3.36 M(-39.2%) | -$22.35 M(-15.7%) |
| Jun 2010 | - | -$5.54 M(-25.2%) | -$26.51 M(-4.4%) |
| Mar 2010 | - | -$7.41 M(+22.6%) | -$27.75 M(+7.3%) |
| Dec 2009 | -$25.97 M(+35.9%) | -$6.04 M(-19.7%) | -$25.85 M(+5.2%) |
| Sep 2009 | - | -$7.53 M(+11.2%) | -$24.58 M(+18.2%) |
| Jun 2009 | - | -$6.77 M(+22.8%) | -$20.80 M(+5.5%) |
| Mar 2009 | - | -$5.51 M(+15.5%) | -$19.71 M(+3.1%) |
| Dec 2008 | -$19.11 M(+15.8%) | -$4.77 M(+27.3%) | -$19.11 M(-2.8%) |
| Sep 2008 | - | -$3.75 M(-34.1%) | -$19.67 M(+0.6%) |
| Jun 2008 | - | -$5.68 M(+15.7%) | -$19.56 M(+68.2%) |
| Mar 2008 | - | -$4.91 M(-7.8%) | -$11.62 M(+22.8%) |
| Dec 2007 | -$16.50 M(+13.6%) | -$5.33 M(+46.5%) | -$9.46 M(+4.2%) |
| Sep 2007 | - | -$3.64 M(-261.7%) | -$9.08 M(+2.5%) |
| Jun 2007 | - | $2.25 M(-181.8%) | -$8.85 M(-17.7%) |
| Mar 2007 | - | -$2.75 M(-44.3%) | -$10.76 M(+38.4%) |
| Dec 2006 | -$14.53 M(-4567.8%) | -$4.94 M(+44.9%) | -$7.78 M(+191.9%) |
| Sep 2006 | - | -$3.41 M(-1109.3%) | -$2.66 M(-395.0%) |
| Jun 2006 | - | $337.90 K(+42.3%) | $903.10 K(+59.8%) |
| Mar 2006 | - | $237.40 K(+38.6%) | $565.20 K(+72.4%) |
| Dec 2005 | $325.30 K | $171.30 K(+9.5%) | $327.80 K(+109.5%) |
| Sep 2005 | - | $156.50 K | $156.50 K |
FAQ
- What is Altimmune annual earnings before interest & taxes?
- What is the all time high annual EBIT for Altimmune?
- What is Altimmune annual EBIT year-on-year change?
- What is Altimmune quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Altimmune?
- What is Altimmune quarterly EBIT year-on-year change?
- What is Altimmune TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Altimmune?
- What is Altimmune TTM EBIT year-on-year change?
What is Altimmune annual earnings before interest & taxes?
The current annual EBIT of ALT is -$88.41 M
What is the all time high annual EBIT for Altimmune?
Altimmune all-time high annual earnings before interest & taxes is $325.30 K
What is Altimmune annual EBIT year-on-year change?
Over the past year, ALT annual earnings before interest & taxes has changed by -$3.51 M (-4.13%)
What is Altimmune quarterly earnings before interest & taxes?
The current quarterly EBIT of ALT is -$22.84 M
What is the all time high quarterly EBIT for Altimmune?
Altimmune all-time high quarterly earnings before interest & taxes is $2.25 M
What is Altimmune quarterly EBIT year-on-year change?
Over the past year, ALT quarterly earnings before interest & taxes has changed by +$8.80 M (+27.81%)
What is Altimmune TTM earnings before interest & taxes?
The current TTM EBIT of ALT is -$103.51 M
What is the all time high TTM EBIT for Altimmune?
Altimmune all-time high TTM earnings before interest & taxes is $903.10 K
What is Altimmune TTM EBIT year-on-year change?
Over the past year, ALT TTM earnings before interest & taxes has changed by -$15.10 M (-17.08%)